Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16763642rdf:typepubmed:Citationlld:pubmed
pubmed-article:16763642lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:16763642lifeskim:mentionsumls-concept:C0936223lld:lifeskim
pubmed-article:16763642lifeskim:mentionsumls-concept:C0162488lld:lifeskim
pubmed-article:16763642lifeskim:mentionsumls-concept:C1518823lld:lifeskim
pubmed-article:16763642pubmed:issue6lld:pubmed
pubmed-article:16763642pubmed:dateCreated2006-6-9lld:pubmed
pubmed-article:16763642pubmed:languageenglld:pubmed
pubmed-article:16763642pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16763642pubmed:citationSubsetIMlld:pubmed
pubmed-article:16763642pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16763642pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16763642pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16763642pubmed:statusMEDLINElld:pubmed
pubmed-article:16763642pubmed:monthJunlld:pubmed
pubmed-article:16763642pubmed:issn1743-4270lld:pubmed
pubmed-article:16763642pubmed:authorpubmed-author:WardJohn FJFlld:pubmed
pubmed-article:16763642pubmed:issnTypePrintlld:pubmed
pubmed-article:16763642pubmed:volume3lld:pubmed
pubmed-article:16763642pubmed:ownerNLMlld:pubmed
pubmed-article:16763642pubmed:authorsCompleteYlld:pubmed
pubmed-article:16763642pubmed:pagination310-1lld:pubmed
pubmed-article:16763642pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:16763642pubmed:meshHeadingpubmed-meshheading:16763642...lld:pubmed
pubmed-article:16763642pubmed:meshHeadingpubmed-meshheading:16763642...lld:pubmed
pubmed-article:16763642pubmed:meshHeadingpubmed-meshheading:16763642...lld:pubmed
pubmed-article:16763642pubmed:meshHeadingpubmed-meshheading:16763642...lld:pubmed
pubmed-article:16763642pubmed:meshHeadingpubmed-meshheading:16763642...lld:pubmed
pubmed-article:16763642pubmed:meshHeadingpubmed-meshheading:16763642...lld:pubmed
pubmed-article:16763642pubmed:meshHeadingpubmed-meshheading:16763642...lld:pubmed
pubmed-article:16763642pubmed:meshHeadingpubmed-meshheading:16763642...lld:pubmed
pubmed-article:16763642pubmed:meshHeadingpubmed-meshheading:16763642...lld:pubmed
pubmed-article:16763642pubmed:meshHeadingpubmed-meshheading:16763642...lld:pubmed
pubmed-article:16763642pubmed:meshHeadingpubmed-meshheading:16763642...lld:pubmed
pubmed-article:16763642pubmed:meshHeadingpubmed-meshheading:16763642...lld:pubmed
pubmed-article:16763642pubmed:meshHeadingpubmed-meshheading:16763642...lld:pubmed
pubmed-article:16763642pubmed:meshHeadingpubmed-meshheading:16763642...lld:pubmed
pubmed-article:16763642pubmed:meshHeadingpubmed-meshheading:16763642...lld:pubmed
pubmed-article:16763642pubmed:year2006lld:pubmed
pubmed-article:16763642pubmed:articleTitleCan PSA velocity serve as a surrogate endpoint in trials of hormone-refractory, metastatic prostate cancer?lld:pubmed
pubmed-article:16763642pubmed:affiliationNevada Cancer Institute, Las Vegas, NV 89135, USA. jward@nvcancer.orglld:pubmed
pubmed-article:16763642pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16763642pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:16763642pubmed:publicationTypeMeta-Analysislld:pubmed